Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 648

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 648
---
 proceeding in advance of its final

disposition, provided that such director presents to FutureTech a written undertaking to repay such amount if it shall ultimately be determined that such director is not entitled to be indemnified by FutureTech.

As permitted by Section 102(b)(7) of the DGCL, FutureTech’s Certificate of Incorporation (as will be in effect upon completion of the Business Combination) contains provisions eliminating the personal liability of directors to FutureTech or its stockholders for monetary damages for breach of fiduciary duty as a director to the fullest extent permitted under the DGCL.

FutureTech expects to maintain standard policies of insurance under which coverage is provided (a) to its directors and officers against losses arising from claims made by reason of breach of duty or other wrongful act by such persons in their respective capacities as officers and directors FutureTech, and (b) to FutureTech with respect to payments which may be made by the registrant to such officers and directors pursuant to the above indemnification provision or otherwise as a matter of law.

| II-1 |

Item 21. Exhibits and Financial Statement Schedules.

(a) Exhibits.

| Exhibit 
 Number  |     | Description                                                                                                                                                                                                                                                                                |
| 1.1     |     | Underwriting                                                                                                                                                                                                                                                                               
 Agreement, dated February 15, 2022, between the Company and EF Hutton, division of Benchmark Investments, LLC, as representative                                                                                                                                                           
 of the underwriters named therein (incorporated by reference to Exhibit 1.1 to the Company’s Form 8-K (File No. 001-41289),                                                                                                                                                                
 filed with the SEC on February 24, 2022)                                                                                                                                                                                                                                                   |
| 2.1+    |     | Agreement                                                                                                                                                                                                                                                                                  
 and Plan of Merger, dated September 16, 2024 by and among FutureTech II Acquisition Corp., Longevity Biomedical, Inc., LBI Merger                                                                                                                                                          
 Sub, Inc., and Bradford A. Zakes (in his capacity as Seller Representative) (incorporated by reference to Exhibit 2.1 to the Company’s                                                                                                                                                     
 Form 8-K (File No. 001-41289), filed with the SEC on September 20, 2024)                                                                                                                                                                                                                   |
| 2.2     |     | Contribution                                                                                                                                                                                                                                                                               
 and Exchange Agreement, by and among Longevity Biomedical, Inc., Cerevast Medical, Inc., the Owners and Bradford A. Zakes (in his                                                                                                                                                          
 capacity as